Why the study?
Does NSAID use affect the risk of cardiovascular events and mortality in patients with inflammation?
Does NSAID use affect the risk of cardiovascular events and mortality in patients with inflammation?
In patients with inflammatory conditions, NSAID use may reduce cardiovascular risk and all-cause mortality due to their anti-inflammatory effects, challenging the conventional belief of universally increased cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Indication bias may explain apparent NSAID CV risks; challenges prior meta-analyses and leaves open true effects in inflammation.
INTRODUCTION: Therapeutic efficiency of NSAID is handicapped by ongoing discussion of cardiovascular (CV) safety. Areas covered: We update meta-analyses on NSAIDs in patients with and without cardiovascular (CV) diseases and analyse the association between NSAIDs and cardiovascular events in patients with inflammation. We demonstrate the substantial influence of an indication bias and confounding, which falsely increase the CV risk. We demonstrate protective cardiovascular effects of NSAIDs due to their anti-inflammatory activity, in particular in patients with rheumatoid arthritis, osteoarthritis or inflammatory pain. Expert commentary: t-NSAIDs and Coxibes drugs resemble in their observed CV risk which, in contrast, reflects the intrinsic risk of patients with pain and inflammation. The anti-inflammatory NSAIDs reduce the risk of first myocardial infarction in patients with inflammation and elevated CRP. The extended use of NSAIDs is not associated with an increased CV risk in patients with pain and inflammation but with reduction in all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Zingler et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: